PTK2 and breast cancer: Our findings suggest that EC expression of activated FAK (EC-pY397-FAK) may be an independent prognostic biomarker for chemotherapy response in patients with advanced breast cancer who received neoadjuvant chemotherapy followed by adjuvant therapy.